A Study of Sacituzumab Govitecan in People With Mesothelioma

Study summary

Participants will receive sacituzumab govitecan until their disease gets worse (progresses), they have severe side effects and cannot continue study treatment, or the participants or the study doctor thinks it's in your best interest to stop treatment.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedSacituzumab govitecan-hziy

The study team can explain what participation involves.

Who it may be forMesothelioma

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 28, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 2

Interventional

Where is it offered?7 U.S. locations

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Phase 2
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Drug: Sacituzumab govitecan-hziy

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Mesothelioma→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Patient, or legally authorized representative (LAR), willing and able to provide written informed consent for the trial
Patient age ≥ 18 at time of consent
Pathologically confirmed diffuse pleural mesothelioma
Must have received at least one prior systemic therapy (platinum/pemetrexed, immunotherapy or a combination thereof)
Measurable disease as defined primarily by the modified RECIST criteria for mesothelioma (at PI discretion RECIST v1.1 may be used)
Consent to undergo a biopsy prior to Cycle 1 Day 1 and Cycle 3 Day 1 if deemed medically safe and feasible
Eastern Cooperative Oncology Group (ECOG) score 0 or Karnofsky Performance Status ≥ 70%
Adequate organ function, defined as
Absolute neutrophil count ≥ 1.5K/mcL
Platelet count ≥ 100K/mcL
Adequate renal function defined as creatinine clearance ≥ 30ml/min (as calculated by Cockcroft-Gault Formula)
Hemoglobin \> 9g/dL (prior transfusion permitted if not within 7 days of enrollment)
Total bilirubin ≤1.5 x upper limit of normal (ULN) if no liver metastases or \<3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinemia) or liver metastases; subjects with Gilbert's syndrome can enroll if conjugated bilirubin is within normal limits
AST, ALT ≤ 2.5 x ULN (if liver metastases are present, ≤5 × ULN)
If of childbearing potential, must be willing to use highly effective mode of contraception for at least one month prior, during, and for 2 months after the end of active therapy

Reasons someone may not be able to joinExclusion criteria

Currently participating in another study and receiving another study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 3 weeks of the first dose of treatment
Prior hypersensitivity to irinotecan or any components of sacituzumab govitecan-hziy
Prior cytotoxic/immunologic systemic therapy within 3 weeks prior to study Day 1 or has not recovered (i.e., CTCAE v5 ≥ Grade 1 at baseline; from clinically significant adverse events due to a previously administered agent (excluding Grade 2 neuropathy)
Known psychiatric or substance abuse disorders that would interfere with the requirements of the trial within the opinion of the investigator
Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, early stage prostate cancer, or in situ cervical cancer after definitive treatment
Positive hepatitis B (hepatitis B virus \[HBV\]) surface antigen (HBsAg) o NOTE: Subjects with a prior history of HBV demonstrated by positive hepatitis B core antibody are eligible if they have at Screening 1) a negative HBsAg and 2) a HBV DNA (viral load) below the lower limit of quantification, per local testing. Patients who fit these criteria must use Hep B prophylaxis during treatment. Subjects with a positive HBsAg due to recent vaccination are eligible if HBV DNA (viral load) is below the lower limit of quantification, per local testing
Positive hepatitis C antibody (anti-HCV) o NOTE: Subjects with a prior history of HCV, who have completed antiviral treatment and have subsequently documented HCV RNA below the lower limit of quantification per local testing are eligible
Participant is positive for human immunodeficiency virus (HIV), with 1 or more of the following:
Receiving ART that may interfere with study treatment (consult sponsor for review of medication prior to enrollment)
CD4 count \< 350 cells/mm3 at screening
AIDS-defining opportunistic infection within 6 months of start of screening
Not agreeing to start ART and be on ART \> 4 weeks plus having HIV viral load \<400 copies/mL at end of 4-week period (to ensure ART is tolerated and HIV controlled)
Myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), or coronary/peripheral artery bypass graft, or any acute coronary syndrome within 6 months of start of study drug
Congestive heart failure defined as New York Heart Association (NYHA) Class III-IV or hospitalization for congestive heart failure (any NYHA class) within 6 months of study Day 1
Pregnant women or women who are breastfeeding or of childbearing potential and not using a highly effective method of birth control for at least one month prior to enrollment. If the risk of contraception exists, male and female subjects must use highly effective contraception throughout the study and for at least 60 days after last treatment. Highly effective contraception includes either 2 barrier methods (diaphragm, condom by the partner, copper intrauterine device, sponge, or spermicide), or 1 barrier method and 1 hormonal method (any oral, subcutaneous, intrauterine, or intramuscular registered and marketed contraceptive agent that contains an estrogen and/or a progesterone agent)

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memorial Sloan Kettering Basking RidgeBasking Ridge, New Jersey
Memorial Sloan Kettering MonmouthMiddletown, New Jersey
Memorial Sloan Kettering BergenMontvale, New Jersey
Memorial Sloan Kettering Cancer Center @ CommackCommack, New York
Memorial Sloan Kettering WestchesterHarrison, New York
Memorial Sloan - Kettering Cancer CenterNew York, New York
Memorial Sloan Kettering NassauUniondale, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 28, 2026. Always confirm current availability with the study team.

View original record ↗